Alzheimer's drug from Eli Lilly gets recommendation from FDA advisory panel
An advisory panel to the FDA recently analysed the trial for donanemab, the experimental Alzheimer's drug from Eli Lilly, to determine whether they deemed it safe enough to use in patients, even amid concerns over some of the adverse effects seen with the drug.
The advisors, who are independent of the FDA, were required to vote on whether the experimental treatment’s benefit to patients supersede the risks. The results were unanimous in favour of the treatment.
The advisory panel were asked to consider the design and results of the clinical trial of the drug. It was pointed out that the trial outline was significantly different to the trial for similar neurodegeneration therapeutic Leqembi, from Eisai and Biogen, which has already successfully been granted approval from the FDA are going through a similar process.
Both therapies focus on the removal of beta amyloid plaques from the brains of people who are in the early stages of Alzheimer’s disease, and the results of these have both been positive, showing the slowing in disease progression and decline in patients.
In the trial donanemab is administered via infusion, once every month.
Prior to the start of the donanemab trial, the levels of the tau protein, which is associated with brain cell death, were measured with the aim of identifying patients that would be more likely to demonstrate a difference over the course of the 76 weeks of the trial. This led to the exclusion of patients with low or no tau protein levels. The advisory panel indicated that this data could suggest the treatment is beneficial, but that testing for tau levels should not be a requirement before treatment is started as this could limit the access to patients.
"We really are pleased that the advisory committee recognised donanemab's strong positive benefit risk," stated Dawn Brooks, Lilly's development leader for donanemab, after the vote.
The patients experienced slowed progression in memory and thinking problems, by 29% over the course of the trial. In terms of safety, there are a number of concerns specifically around swelling and bleeding in the brain, which commonly coincides with the application of this class of drugs. Swelling occurred in 24% of patients and bleeding the brain 31%, and three patients in the trial died.
However, the trial design from Lilly was made to reduce risks as much as possible, where regularly brain imaging was conducted, and the patients were able to stop treatment as soon as the amyloid plaques were seen to be cleared, limiting any unnecessary risks for the patients.
Committee recommendation doesn’t necessarily guarantee approval from the FDA, but in most cases the FDA have been known to follow to the advisory board, suggesting a positive outcome for Lilly’s Alzheimer’s drug.
Source:
Reuters. Lilly Alzheimer's drug gets unanimous backing from FDA advisory panel. [Date accessed 14/06/2024] www.reuters.com/business/healthcare-pharmaceuticals/us-fda-advisers-review-eli-lilly-alzheimers-drug-2024-06-10/
Related News
-
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News Sanofi to collaborate with OpenAI and Formation Bio
Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development. -
News Women in Pharma: Delivering personal and professional success
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Eisai begins US FDA rolling submission for Alzheimer’s drug Leqembi
Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi. -
News Racial disparities in diagnosis and drug use for dementia symptoms
A study from the USC Schaeffer Center for Health Policy & Economics has revealed the existence of racial disparities in the US for the diagnosis of dementia and the use of drug treatments for symptoms. -
News MDMA-assisted therapy for PTSD to be reviewed by US FDA
American public benefit corporation (PBC) Lykos Therapeutics have announced that the US FDA Psychopharmacologic Drugs Advisory Committee (PDAC) will review data supporting their new drug application (NDA) for MDMA capsules, which are to be used in comb...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance